• / Free eNewsletters & Magazine
  • / My Account
Home>Meda to acquire Rottapharm, creating a European specialty pharma leader

Meda to acquire Rottapharm, creating a European specialty pharma leader

3party Content

Thu, 31 Jul 2014

Regulatory News: Meda (STO:MEDAA): The combined entity will have enhanced scale, reach and profitability with 2013 pro-forma revenue and EBITDA of SEK 18 billion (€1.9
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.